| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income, net | 534 | 744 | - | 1,156 |
| Net loss before income taxes | -7,382 | - | - | -17,437 |
| Income tax benefit | 0 | - | - | -290 |
| Net loss and comprehensive loss | -7,382 | -1,700 | - | -17,147 |
| Earnings per share, basic | -0.13 | -0.03 | -0.25 | -0.32 |
| Earnings per share, diluted | -0.13 | -0.03 | -0.25 | -0.32 |
| Weighted average number of shares outstanding, basic | 56,280,844 | 56,026,767 | 55,376,188 | 54,124,862 |
| Weighted average number of shares outstanding, diluted | 56,280,844 | 56,026,767 | 55,376,188 | 54,124,862 |
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)